Oncology

Back to articles

Long-term use of imatinib safe and effective for CML

KEY POINT

For patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase who were initiated on imatinib, long-term follow-up over a decade showed that the estimated overall survival rate was 83%, complete cytogenetic response occurred in 82.8% of patients, and no new safety signals emerged over time.

SOURCES

Hochhaus A, et al. Long-term outcomes for imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927.

Long DL. Imatinib changed everything. N Engl J Med. 2017;376(10):982–983.